Skip to main content
SpringerLink
Log in

Reproductive Organ Signs

  • Chapter
  • First Online:
Endocrine Pathophysiology

  • 637 Accesses

Abstract

Knowledge of the physiology of male and female reproductive organs is critical to our understanding of perturbations in hormonal systems, which result in the physical manifestations of conditions such as polycystic ovary syndrome, congenital adrenal hyperplasia, androgen insensitivity syndrome, estrogen resistance, and menopause.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ouarezki Y, Cizmecioglu FM, Mansour C, Jones JH, Gault EJ, Mason A, Donaldson MDC. Measured parental height in turner syndrome—a valuable but underused diagnostic tool. Eur J Pediatr. 2018;177:171–9.

    PubMed  Google Scholar 

  2. Quigley CA, Crowe BJ, Anglin DG, Chipman JJ. Growth hormone and low dose estrogen in turner syndrome: results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab. 2002;87:2033–41.

    CAS  PubMed  Google Scholar 

  3. Seo GH, Kang E, Cho JH, Lee BH, Choi J-H, Kim G-H, Seo E-J, Yoo H-W. Turner syndrome presented with tall stature due to overdosage of the SHOX gene. Ann Pediatr Endocrinol Metab. 2015;20:110–3.

    PubMed  PubMed Central  Google Scholar 

  4. Oliveira CS, Alves C. The role of the SHOX gene in the pathophysiology of turner syndrome. Endocrinol Nutr. 2011;58:433–42.

    CAS  PubMed  Google Scholar 

  5. Ross JL, Kowal K, Quigley CA, Blum WF, Cutler GB, Crowe B, Hovanes K, Elder FF, Zinn AR. The phenotype of short stature Homeobox gene (SHOX) deficiency in childhood: contrasting children with Leri-Weill Dyschondrosteosis and turner syndrome. J Pediatr. 2005;147:499–507.

    CAS  PubMed  Google Scholar 

  6. Zhong Q, Layman LC. Genetic Considerations in the Patient with Turner Syndrome—45,X with or without Mosaicism. Fertil Steril. 2012;98:775–9.

    PubMed  PubMed Central  Google Scholar 

  7. Shankar RK, Backeljauw PF. Current best practice in the management of turner syndrome. Ther Adv Endocrinol Metab. 2018;9:33–40.

    PubMed  Google Scholar 

  8. Atton G, Gordon K, Brice G, Keeley V, Riches K, Ostergaard P, Mortimer P, Mansour S. The lymphatic phenotype in turner syndrome: an evaluation of nineteen patients and literature review. Eur J Hum Genet. 2015;23:1634–9.

    PubMed  PubMed Central  Google Scholar 

  9. De Groote K, Demulier L, De Backer J, De Wolf D, De Schepper J, Tʼsjoen G, De Backer T. Arterial hypertension in turner syndrome: a review of the literature and a practical approach for diagnosis and treatment. J Hypertens. 2015;33:1342–51.

    PubMed  Google Scholar 

  10. Evan L, Emilio Q, Zunqiu C, Jodi L, Michael S. Pilot study of blood pressure in girls with turner syndrome. Hypertension. 2016;68:133–6.

    Google Scholar 

  11. Becker B, Jospe N, Goldsmith LA. Melanocytic nevi in turner syndrome. Pediatr Dermatol. 1994;11:120–4.

    CAS  PubMed  Google Scholar 

  12. Gibbs P, Brady BM, Gonzalez R, Robinson WA. Nevi and melanoma: lessons from Turner’s syndrome. Dermatology (Basel). 2001;202:1–3.

    CAS  Google Scholar 

  13. Abir R, Fisch B, Nahum R, Orvieto R, Nitke S, Ben Rafael Z. Turner’s syndrome and fertility: current status and possible putative prospects. Hum Reprod Update. 2001;7:603–10.

    CAS  PubMed  Google Scholar 

  14. Bakalov VK, Cheng C, Zhou J, Bondy CA. X-chromosome gene dosage and the risk of diabetes in turner syndrome. J Clin Endocrinol Metabol. 2009;94:3289–96.

    CAS  Google Scholar 

  15. Collett-Solberg PF, Gallicchio CT, Da Coelho SSC Siqueira RA, De Alves STF, Guimarães MM (2011) Endocrine diseases, perspectives and care in turner syndrome. Arq Bras Endocrinol Metabol 55:550–558.

    PubMed  Google Scholar 

  16. Feng J-G, Guo Y, Ma L-A, Xing J, Sun R-F, Zhu W. Prevalence of dermatologic manifestations and metabolic biomarkers in women with polycystic ovary syndrome in North China. J Cosmet Dermatol. 2018;17:511–7.

    PubMed  Google Scholar 

  17. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–7.

    CAS  PubMed  Google Scholar 

  18. Cook H, Brennan K, Azziz R. Reanalyzing the modified ferriman-gallwey score: is there a simpler method for assessing the extent of hirsutism? Fertil Steril. 2011;96:1266–1270.e1.

    PubMed  PubMed Central  Google Scholar 

  19. Aswini R, Jayapalan S. Modified Ferriman–Gallwey score in hirsutism and its association with metabolic syndrome. Int J Trichology. 2017;9:7–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;140:815–30.

    CAS  PubMed  Google Scholar 

  21. Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med. 2005;353:2578–88.

    CAS  PubMed  Google Scholar 

  22. Coskun A, Ercan O, Arikan DC, Özer A, Kilinc M, Kiran G, Kostu B. Modified Ferriman–Gallwey hirsutism score and androgen levels in Turkish women. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2011;154:167–71.

    CAS  PubMed  Google Scholar 

  23. Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the androgen excess and polycystic ovary syndrome society. Hum Reprod Update. 2012;18:146–70.

    CAS  PubMed  Google Scholar 

  24. Martin KA, Anderson RR, Chang RJ, Ehrmann DA, Lobo RA, Murad MH, Pugeat MM, Rosenfield RL. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103:1233–57.

    PubMed  Google Scholar 

  25. Mihailidis J, Dermesropian R, Taxel P, Luthra P, Grant-Kels JM. Endocrine evaluation of hirsutism. Int J Womens Dermatol. 2017;3:S6–S10.

    PubMed  PubMed Central  Google Scholar 

  26. Panidis D, Skiadopoulos S, Rousso D, Ioannides D, Panidou E. Association of acanthosis nigricans with insulin resistance in patients with polycystic ovary syndrome. Br J Dermatol. 1995;132:936–41.

    CAS  PubMed  Google Scholar 

  27. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 2005;90:4650–8.

    CAS  PubMed  Google Scholar 

  28. Chuan SS, Chang RJ. Polycystic ovary syndrome and acne. Skin Therapy Lett. 2010;15:1–4.

    PubMed  Google Scholar 

  29. Ju Q, Tao T, Hu T, Karadağ AS, Al-Khuzaei S, Chen W. Sex hormones and acne. Clin Dermatol. 2017;35:130–7.

    PubMed  Google Scholar 

  30. Khezrian L, Yazdanfar A, Azizian Z, Hassani P, Feyzian M. The relationship between acne and other Hyperandrogenism signs. Journal of Skin and Stem Cell. 2016;3:e64187.

    Google Scholar 

  31. Sam S. Obesity and polycystic ovary syndrome. Obes Manag. 2007;3:69–73.

    PubMed  PubMed Central  Google Scholar 

  32. Boumosleh JM, Grundy SM, Phan J, Neeland IJ, Chang A, Vega GL. Metabolic concomitants of obese and nonobese women with features of polycystic ovarian syndrome. J Endocr Soc. 2017;1:1417–27.

    PubMed  PubMed Central  Google Scholar 

  33. Leondires MP, Berga SL. Role of GnRH drive in the pathophysiology of polycystic ovary syndrome. J Endocrinol Investig. 1998;21:476–85.

    CAS  Google Scholar 

  34. Chaudhari N, Dawalbhakta M, Nampoothiri L. GnRH dysregulation in polycystic ovarian syndrome (PCOS) is a manifestation of an altered neurotransmitter profile. Reprod Biol Endocrinol. 2018;16:37.

    PubMed  PubMed Central  Google Scholar 

  35. Johansson J, Stener-Victorin E. Polycystic ovary syndrome: effect and mechanisms of acupuncture for ovulation induction. Evid Based Complement Alternat Med. 2013; https://doi.org/10.1155/2013/762615.

  36. Deswal R, Yadav A, Dang AS. Sex hormone binding globulin - an important biomarker for predicting PCOS risk: a systematic review and meta-analysis. Syst Biol Reprod Med. 2018;64:12–24.

    CAS  PubMed  Google Scholar 

  37. Mehrabian F, Afghahi M. Can sex-hormone binding globulin considered as a predictor of response to pharmacological treatment in women with polycystic ovary syndrome? Int J Prev Med. 2013;4:1169–74.

    PubMed  PubMed Central  Google Scholar 

  38. Bremer AA. Polycystic ovary syndrome in the pediatric population. Metab Syndr Relat Disord. 2010;8:375–94.

    PubMed  PubMed Central  Google Scholar 

  39. Baskind NE, Balen AH. Hypothalamic-pituitary, ovarian and adrenal contributions to polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2016;37:80–97.

    PubMed  Google Scholar 

  40. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774–800.

    CAS  PubMed  Google Scholar 

  41. Yazıcı D, Sezer H. Insulin resistance, obesity and lipotoxicity. Adv Exp Med Biol. 2017;960:277–304.

    PubMed  Google Scholar 

  42. Chen X, Jia X, Qiao J, Guan Y, Kang J. Adipokines in reproductive function: a link between obesity and polycystic ovary syndrome. J Mol Endocrinol. 2013;50:R21–37.

    CAS  PubMed  Google Scholar 

  43. Dimitriadis GK, Kyrou I, Randeva HS. Polycystic ovary syndrome as a Proinflammatory state: the role of Adipokines. Curr Pharm Des. 2016;22:5535–46.

    CAS  PubMed  Google Scholar 

  44. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4565–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Ruiz-Olvera SF, Rajmil O, Sanchez-Curbelo J-R, Vinay J, Rodriguez-Espinosa J, Ruiz-Castañé E. Association of serum testosterone levels and testicular volume in adult patients. Andrologia. 2018;50:e12933.

    Google Scholar 

  46. Basaria S. Male hypogonadism. Lancet. 2014;383:1250–63.

    CAS  PubMed  Google Scholar 

  47. Sakamoto H, Saito K, Ogawa Y, Yoshida H. Testicular volume measurements using Prader Orchidometer versus ultrasonography in patients with infertility. Urology. 2007;69:158–62.

    PubMed  Google Scholar 

  48. Handelsman DJ, Staraj S. Testicular size: the effects of aging, malnutrition, and illness. J Androl. 1985;6:144–51.

    CAS  PubMed  Google Scholar 

  49. Barrionuevo F, Burgos M, Jiménez R. Origin and function of embryonic Sertoli cells. Biomol Concepts. 2011;2:537–47.

    CAS  PubMed  Google Scholar 

  50. Griswold MD. The central role of Sertoli cells in spermatogenesis. Semin Cell Dev Biol. 1998;9:411–6.

    CAS  PubMed  Google Scholar 

  51. Shalet SM. Normal testicular function and spermatogenesis. Pediatr Blood Cancer. 2009;53:285–8.

    PubMed  Google Scholar 

  52. Stocco C. Tissue physiology and pathology of aromatase. Steroids. 2012;77:27–35.

    CAS  PubMed  Google Scholar 

  53. Vaucher L, Funaro MG, Mehta A, Mielnik A, Bolyakov A, Prossnitz ER, Schlegel PN, Paduch DA. Activation of GPER-1 estradiol receptor downregulates production of testosterone in isolated rat Leydig cells and adult human testis. PLoS One. 2014;9:e92425.

    PubMed  PubMed Central  Google Scholar 

  54. Demyashkin GA. Inhibin B in seminiferous tubules of human testes in normal spermatogenesis and in idiopathic infertility. Syst Biol Reprod Med. 2019;65:20–8.

    CAS  PubMed  Google Scholar 

  55. Lin C-C, Huang WJS, Chen K-K. Measurement of testicular volume in smaller testes: how accurate is the conventional Orchidometer? J Androl. 2009;30:685–9.

    PubMed  Google Scholar 

  56. Carlson HE. Approach to the patient with gynecomastia. J Clin Endocrinol Metab. 2011;96:15–21.

    CAS  PubMed  Google Scholar 

  57. Meerkotter D. Gynaecomastia associated with highly active antiretroviral therapy (HAART). J Radiol Case Rep. 2010;4:34–40.

    PubMed  PubMed Central  Google Scholar 

  58. Ryan CS, Petkov VI, Adler RA. Osteoporosis in men: the value of laboratory testing. Osteoporos Int. 2011;22:1845–53.

    CAS  PubMed  Google Scholar 

  59. Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab. 2012;23:576–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Szulc P, Claustrat B, Marchand F, Delmas PD. Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metabol. 2003;88:5240–7.

    CAS  Google Scholar 

  61. Rochira V, Kara E, Carani C. The endocrine role of estrogens on human male skeleton. Int J Endocrinol. 2015; https://doi.org/10.1155/2015/165215.

  62. Skinner JW, Otzel DM, Bowser A, Nargi D, Agarwal S, Peterson MD, Zou B, Borst SE, Yarrow JF. Muscular responses to testosterone replacement vary by administration route: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2018;9:465–81.

    PubMed  PubMed Central  Google Scholar 

  63. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men--a clinical research center study. J Clin Endocrinol Metab. 1996;81:3469–75.

    CAS  PubMed  Google Scholar 

  64. Nieschlag E. Klinefelter Syndrome. Dtsch Arztebl Int. 2013;110:347–53.

    PubMed  PubMed Central  Google Scholar 

  65. Bonomi M, Rochira V, Pasquali D, Balercia G, Jannini EA, Ferlin A. Klinefelter syndrome (KS): genetics, clinical phenotype and hypogonadism. J Endocrinol Investig. 2017;40:123–34.

    CAS  Google Scholar 

  66. Urysiak-Czubatka I, Kmieć ML, Broniarczyk-Dyła G. Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia. Postepy Dermatol Alergol. 2014;31:207–15.

    PubMed  PubMed Central  Google Scholar 

  67. El Kassar N, Hetet G, Brière J, Grandchamp B. X-chromosome inactivation in healthy females: incidence of excessive lyonization with age and comparison of assays involving DNA methylation and transcript polymorphisms. Clin Chem. 1998;44:61–7.

    PubMed  Google Scholar 

  68. Groth KA, Skakkebæk A, Høst C, Gravholt CH, Bojesen A. Klinefelter syndrome—a clinical update. J Clin Endocrinol Metab. 2013;98:20–30.

    CAS  PubMed  Google Scholar 

  69. Terribile M, Stizzo M, Manfredi C, Quattrone C, Bottone F, Giordano RD, Bellastella G, Arcaniolo D, De Sio M. 46,XX Testicular Disorder of Sex Development (DSD): A Case Report and Systematic Review. Medicina. 2019; https://doi.org/10.3390/medicina55070371.

  70. Li T-F, Wu Q-Y, Zhang C, Li W-W, Zhou Q, Jiang W-J, Cui Y-X, Xia X-Y, Shi Y-C. 46,XX testicular disorder of sexual development with SRY-negative caused by some unidentified mechanisms: a case report and review of the literature. BMC Urol. 2014;14:104.

    PubMed  PubMed Central  Google Scholar 

  71. Huang AJ, Moore EE, Boyko EJ, Scholes D, Lin F, Vittinghoff E, Fihn SD. Vaginal symptoms in postmenopausal women: self-reported severity, natural history, and risk factors. Menopause. 2010;17:121–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Waetjen LE, Crawford SL, Chang P, Reed BD, Hess R, Avis NE, Harlow SD, Greendale GA, Dugan SA, Gold EB. Factors associated with developing vaginal dryness symptoms in women transitioning through menopause: a longitudinal study. Menopause. 2018;25:1094–104.

    PubMed  PubMed Central  Google Scholar 

  73. Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. Endocrinol Metab Clin N Am. 2015;44:497–515.

    Google Scholar 

  74. Nair PA. Dermatosis associated with menopause. J Midlife Health. 2014;5:168–75.

    PubMed  PubMed Central  Google Scholar 

  75. Shah M, Karena Z, Patel SV, Parmar N, Singh PK, Sharma A. Treatment of vaginal atrophy with vaginal estrogen cream in menopausal Indian women. Oman Med J. 2017;32:15–9.

    PubMed  PubMed Central  Google Scholar 

  76. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85:87–94.

    PubMed  PubMed Central  Google Scholar 

  77. Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab. 2008;93:861–8.

    CAS  PubMed  Google Scholar 

  78. Manolagas SC, O’Brien CA, Almeida M. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2013;9:699–712.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Wang J, Zhang W, Yu C, Zhang X, Zhang H, Guan Q, Zhao J, Xu J. Follicle-stimulating hormone increases the risk of postmenopausal osteoporosis by stimulating osteoclast differentiation. PLoS One. 2015; https://doi.org/10.1371/journal.pone.0134986.

  80. Chin K-Y. The relationship between follicle-stimulating hormone and bone health: alternative explanation for bone loss beyond Oestrogen? Int J Med Sci. 2018;15:1373–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Barbat-Artigas S, Aubertin-Leheudre M. Menopausal transition and fat distribution. Menopause. 2013;20:370.

    PubMed  Google Scholar 

  82. Lovejoy J, Champagne C, de Jonge L, Xie H, Smith S. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes. 2008;32:949–58.

    CAS  Google Scholar 

  83. Leanne H, Rajarshi B, Belén R, et al. Menopausal Status and Abdominal Obesity Are Significant Determinants of Hepatic Lipid Metabolism in Women. Journal of the American Heart Association. 4:e002258.

    Google Scholar 

  84. Donato GB, Fuchs SC, Oppermann K, Bastos C, Spritzer PM. Association between menopause status and central adiposity measured at different cutoffs of waist circumference and waist-to-hip ratio. Menopause. 2006;13:280–5.

    PubMed  Google Scholar 

  85. Kozakowski J, Gietka-Czernel M, Leszczyńska D, Majos A. Obesity in menopause – our negligence or an unfortunate inevitability? Prz Menopauzalny. 2017;16:61–5.

    PubMed  PubMed Central  Google Scholar 

  86. Freedman RR. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med. 2005;23:117–25.

    PubMed  Google Scholar 

  87. Morrow PKH, Mattair DN, Hortobagyi GN. Hot flashes: a review of pathophysiology and treatment modalities. Oncologist. 2011;16:1658–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Freeman EW, Sammel MD, Sanders RJ. Risk of long term hot flashes after natural menopause: evidence from the penn ovarian aging cohort. Menopause. 2014;21:924–32.

    PubMed  PubMed Central  Google Scholar 

  89. Gordon M, Donald L, Emanuele M, Ann M. Hot flashes in patients with hypogonadism and low serum gon-adotropin levels. Endocr Pract. 2003;9:119–23.

    PubMed  Google Scholar 

  90. Szafran H, Smielak-Korombel W. The role of estrogens in hormonal regulation of lipid metabolism in women. Przeglad lekarski. 1998;55:266–70.

    CAS  PubMed  Google Scholar 

  91. Kumar S, Shah C, Oommen ER. Study of cardiovascular risk factors in pre and postmenopausal women. Int J Pharma Sci Res. 2012;3:560–70.

    Google Scholar 

  92. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331:1056–61.

    CAS  PubMed  Google Scholar 

  93. Bernard V, Kherra S, Francou B, et al. Familial multiplicity of estrogen insensitivity associated with a loss-of-function ESR1 mutation. J Clin Endocrinol Metab. 2016;102:93–9.

    PubMed Central  Google Scholar 

  94. Quaynor SD, Stradtman EW, Kim H-G, Shen Y, Chorich LP, Schreihofer DA, Layman LC. Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant. N Engl J Med. 2013;369:164–71.

    CAS  PubMed  Google Scholar 

  95. Simm PJ, Bajpai A, Russo VC, Werther GA. Estrogens and growth. Pediatr Endocrinol Rev. 2008;6:32–41.

    CAS  PubMed  Google Scholar 

  96. Rodd C, Jourdain N, Alini M. Action of estradiol on epiphyseal growth plate chondrocytes. Calcif Tissue Int. 2004;75:214–24.

    CAS  PubMed  Google Scholar 

  97. Nilsson O, Marino R, De Luca F, Phillip M, Baron J. Endocrine regulation of the growth plate. Horm Res. 2005;64:157–65.

    CAS  PubMed  Google Scholar 

  98. Hewitt SC, Korach KS. Estrogen receptors: new directions in the new millennium. Endocr Rev. 2018;39:664–75.

    PubMed  PubMed Central  Google Scholar 

  99. Lang-Muritano M, Sproll P, Wyss S, Kolly A, Hürlimann R, Konrad D, Biason-Lauber A. Early-onset complete ovarian failure and lack of puberty in a woman with mutated estrogen receptor β (ESR2). J Clin Endocrinol Metab. 2018;103:3748–56.

    PubMed  Google Scholar 

  100. Yang P, Liu X, Gao J, Qu S, Zhang M. Complete androgen insensitivity syndrome in a young woman with metabolic disorder and diabetes: a case report. Medicine (Baltimore). 2018;97:e11353.

    Google Scholar 

  101. Batista RL, Costa EMF, De Rodrigues AS, et al. Androgen insensitivity syndrome: a review. Archives of Endocrinology and Metabolism. 2018;62:227–35.

    PubMed  Google Scholar 

  102. Mendoza N, Motos MA. Androgen insensitivity syndrome. Gynecol Endocrinol. 2013;29:1–5.

    CAS  PubMed  Google Scholar 

  103. Mongan NP, Tadokoro-Cuccaro R, Bunch T, Hughes IA. Androgen insensitivity syndrome. Best Pract Res Clin Endocrinol Metab. 2015;29:569–80.

    CAS  PubMed  Google Scholar 

  104. Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyannopoulou K, MacDougall J. Androgen insensitivity syndrome. Lancet. 2012;380:1419–28.

    CAS  PubMed  Google Scholar 

  105. Nazzaro G, Genovese G, Brena M, Passoni E, Tadini G. Aberrant breast tissue in complete androgen insensitivity syndrome. Clin Exp Dermatol. 2018;43:491–3.

    CAS  PubMed  Google Scholar 

  106. Tadokoro-Cuccaro R, Hughes IA. Androgen insensitivity syndrome. Curr Opin Endocrinol Diabetes Obes. 2014;21:499.

    CAS  PubMed  Google Scholar 

  107. T’Sjoen G, De Cuypere G, Monstrey S, Hoebeke P, Freedman FK, Appari M, Holterhus P-M, Van Borsel J, Cools M. Male gender identity in complete androgen insensitivity syndrome. Arch Sex Behav. 2011;40:635–8.

    PubMed  Google Scholar 

  108. Souhail R, Amine S, Nadia A, Tarik K, Khalid EK, Abdellatif K, Ahmed IA. Complete androgen insensitivity syndrome or testicular feminization: review of literature based on a case report. Pan Afr Med J. 2016; https://doi.org/10.11604/pamj.2016.25.199.10758.

  109. Quigley CA, de Bellis A, Marschke KB, El-Awady MK, Wilson EM, French FS. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev. 1995;16:271–321.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes and Metabolism, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA

    Andrea Manni

  2. Sanford Health Clinic, Bemidji, MN, USA

    Akuffo Quarde

Authors
  1. Andrea Manni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akuffo Quarde
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Manni .

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Manni, A., Quarde, A. (2020). Reproductive Organ Signs. In: Endocrine Pathophysiology. Springer, Cham. https://doi.org/10.1007/978-3-030-49872-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-49872-6_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-49871-9

  • Online ISBN: 978-3-030-49872-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation